Antiamnesic activity of nerve growth factor adsorbed on poly(butyl) cyanoacrylate nanoparticles coated with polysorbate-80

Eksperimental'naya i Klinicheskaya Farmakologiya

Volumn 68, Issue 6, 2005, Pages 3-8

  Basel, A A ^a   Petrov, V E ^a   Trofimov, S S ^b   Voronina, T A ^b   Alyautdin, R N ^a  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^b INSTITUTE OF PHARMACOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ENBUCRILATE; EXCIPIENT; NANOMATERIAL; NERVE GROWTH FACTOR; POLYSORBATE;

AMNESIA; ANIMAL; ARTICLE; AVOIDANCE BEHAVIOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; MALE; RAT; WISTAR RAT;

AMNESIA; ANIMALS; AVOIDANCE LEARNING; ENBUCRILATE; EXCIPIENTS; MALE; NANOSTRUCTURES; NERVE GROWTH FACTOR; POLYSORBATES; RATS; RATS, WISTAR;

EID: 29544450970     PISSN: 08692092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. R. Alyautdin, D. Gothier, V. Petrov, et al., Eur. J. Pharm. Biopharm., 41, 44-48 (1995).
2. R. Alyautdin, V. Petrov, K. Langer, et al., Pharm. Res., 14, 325-328 (1997).
3. R. Alyautdin, E. Tezikov, P. Ramage, et al., J. Microencapsul., 15, 67-74 (1998).
4. M. Bibel, E. Hoope, and Y. A. Brade, EMBOJ, 18, 616-622 (1999).
5. M. Bothwell, Annu. Rev. Neurosci., 18, 223-253 (1995).
6. M. Canossa, O. Griesbeck, V. Berninger, et al., Proc. Natl. Acad. Sci. USA, 94, 13279-13286 (1997).
7. J. Frade and Y. Brade., Bioassays, 20(2), 137-145 (1998).
8. K. Frick, D. Price, V. Koliatsos, et al., J. Neurosci., 17(7), 2543-2550 (1997).
9. W. J. Friedman and L. A. Greene., Exp. Cell Res., 253, 131-142 (1999).
10. S. Furukawa and Y. Furukawa, No To Shinkei, 43(12), 1101-1112 (1991).
11. M. D. Geschwind, C. F. Dreyfus, and L. G. Reichardt, Mol. Brain Res., 24, 327-335 (1994).
12. A. Gessner, C. Olbrich, W. Schroder, et al., Int. J. Pharm., 214(1-2), 87-91 (2001).
13. F. Hefti and W. Weiner, Ann. Neurol., 20(3), 275-281 (1986).
14. E. J. Huang and L. F. Reichardt, Annu. Rev. Biochem., 72, 1801-1807 (2003).
15. C. Humpel and C. Weis, J. Neural. Transm., 62(suppl), 253-263 (2002).
16. M. E. Jonhagen, Alzheimer Dis. Assoc. Disord., 14(Suppl 1), 31-38 (2000).
17. D. Kim, H. Iijima, K. Goto, et al., J. Biol. Chem., 271, 8373-8380 (1996).
18. J. Kreuter, P. Ramge, V. Petrov, et al., Pharm. Res., 20(3), 409-416 (2003).
19. J. Kreuter, D. Shamenkov, V. Petrov, et al., J. Drug targeting, 10(4), 317-325 (2002).
20. J. Kreuter, Adv. Drug Deliv. Rev., 47(1), 65-81 (2001).
21. E. S. Levine, C. F. Dreyfus, I. R. Black, et al., Neurobiology, 92, 8074-8077 (1995).
22. G. R. Lewin and Y. A. Barde, Annu. Rev. Neurosci., 19, 289-317 (1996).
23. V. D. Petkov, A. H. Mosharrof, and V. V. Petkov, Acta. Physiol. Pharmacol. Bulg., 14(1), 3-13 (1988).
24. P. Ramge, R. E. Unger, J. B. Oltrogge, et al., Eur. J. Neurosci., 12(6), 1931-1940 (2000).
25. M. Rattray, Biol. Psychiatry, 49(3), 185-193 (2001).
26. E. M. Shooter, B. A. Yankner, G. E. Landreth, et al., Recent prog. Horm. Res., 37, 417-426 (1981).
27. W. Sun, C. Xie, H. Wang, and Y. Hu., Biomaterials, 25(15), 3065-3071. (2004).
28. N. Takei, T. Numakawa, S. Kozaki, et al., J. Biol Chem., 273(42), 27620-27624 (1998).
29. H. Thoenen and M. Sendtner, Nature Neurosci., 5(Suppl), 1046-1050 (2002).
30. R. G. Thorne and W. H. Frey, Clin. Pharmacokinet., 40(12), 907-946 (2001).